Osteogenesis induced by a bone forming peptide from the prodomain region of BMP-7.
Osteoporosis is a reduction in skeletal mass due to an imbalance between bone formation and bone resorption. Many researchers have tried to develop adjuvants as specific suppressors of bone resorption and stimulators of bone formation for therapeutic purposes in patients with osteoporosis. Therefore, specific stimulators on bone formation are one of therapeutic significance in the treatment of osteoporosis. Until now, the regulation of bone generation has been the focus of bone morphogenetic protein-7 (BMP-7) investigation from mature form. However, new peptides from immature form which has osteogenic activity has not been reported and developments of these proteins are still remained. In this study, we found a new peptide sequence, called bone forming peptide-1 (BFP-1) and have more high activities of osteogenic differentiation compared with BMP-7. BFP-1-treated multipotent bone marrow stromal stem cells (MBSCs) induced the expression levels and activity of alkaline phosphatase (ALP). Moreover, BFP-1 enhanced the levels of CD44, CD47 and CD51 expression as well as increased Ca(2+) content in MBSCs. In current study, radiography at 8 weeks revealed that BFP-1 pretreated-MBSC transplanted animals had strongly increased bone formation compared to that in the BMP-7 pretreated MBSC transplanted animals. Our finding indicates a new insight into peptides from the immature region of BMP-7 can also be useful in the development of adjuvant therapies for bone-related diseases.
Heart Research Center and Cardiovascular Research Institute of Chonnam National University, Gwangju, Republic of Korea.
Hyung Keun
HK
Kim
Ji Hyun
JH
Kim
Dae Sung
DS
Park
Kyung Soon
KS
Park
Seong Soo
SS
Kang
Jun Sik
JS
Lee
Myung Ho
MH
Jeong
Taek Rim
TR
Yoon
D000595:Amino Acid Sequence; D015415:Biomarkers / Q000378:metabolism; D055419:Bone Morphogenetic Protein 7 / Q000096:biosynthesis* / Q000737:chemistry; D001861:Bone Regeneration; D001842:Bone and Bones / Q000378:metabolism; D051928:CD47 Antigen / Q000096:biosynthesis; D002118:Calcium / Q000737:chemistry; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis; D039564:Integrin alphaV / Q000096:biosynthesis; D008969:Molecular Sequence Data; D010012:Osteogenesis / Q000502:physiology*; D010024:Osteoporosis; D010446:Peptide Fragments / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry; D017434:Protein Structure, Tertiary; D012038:Regeneration; D013234:Stem Cells / Q000166:cytology; D013778:Tetrazolium Salts / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D023822:Tissue Engineering / Q000379:methods*
D015415:Biomarkers; D055419:Bone Morphogenetic Protein 7; D051928:CD47 Antigen; D018960:Hyaluronan Receptors; D039564:Integrin alphaV; D010446:Peptide Fragments; D010455:Peptides; D013778:Tetrazolium Salts; D013844:Thiazoles; C576241:bone forming peptide-1; C022616:thiazolyl blue; D002118:Calcium